2024 Revenues ($USD) : $19.62B

Bayer AG reported sales of €46.6 billion (approx. $50.6 billion USD) for the fiscal year ending December 31, 2024, with research and development investments reaching €6.2 billion (approx. $6.7 billion USD). Under CEO Bill Anderson, appointed in 2023, Bayer is undergoing a significant operational restructuring, implementing a new operating model to reduce bureaucracy and streamline operations, including reducing management layers. The company aims for €800 million in savings from this model in 2025, on top of approximately €500 million already realized.
CEO Bill Anderson described 2025 as a "pivotal year" and potentially challenging financially, calling it "the second year in Bayer's turnaround and the most difficult in terms of financial performance." He anticipates improved performance starting in 2026 as strategic initiatives progress and emphasized a focus on product innovation, stating, "great drugs lead the way, not existing franchises."

Bayer continues to manage significant legal challenges related to its Roundup™ herbicide product line. In April 2025, the company petitioned the U.S. Supreme Court to review the Durnell Roundup™ case, arguing that federal labeling laws preempt state-based failure-to-warn claims. Ongoing litigation impacts the ability of its subsidiary, Monsanto, to supply glyphosate-based products, with numerous cases still pending.

In its pharmaceutical pipeline, Bayer highlighted recent developments including the EU approval of Beyonttra™ (acoramidis) in February 2025 for treating transthyretin amyloidosis cardiomyopathy, with European launches starting in April 2025. The investigational treatment for menopause symptoms, elinzanetant, is advancing in development. Additionally, regulatory filings for finerenone for a heart failure indication have been submitted in the EU and Japan, and the U.S. FDA has granted Priority Review for a new heart failure indication for the drug.